Does Your PCOS Patient Have Insulin Resistance?
Yes, your patient with PCOS very likely has insulin resistance—approximately 70-80% of women with PCOS exhibit insulin resistance regardless of body weight, and this should be assumed present until proven otherwise through formal screening. 1, 2
Why Insulin Resistance is Central to PCOS
Insulin resistance is not merely associated with PCOS—it plays a fundamental pathophysiological role in the syndrome itself. The relationship is bidirectional and self-perpetuating:
- Selective insulin resistance occurs where metabolic insulin signaling is impaired, but steroidogenic pathways in the ovary remain insulin-sensitive 1
- This creates a vicious cycle: insulin resistance → compensatory hyperinsulinemia → ovarian androgen overproduction → worsening insulin resistance 3
- The ovary paradoxically remains sensitive to insulin's steroidogenic effects even when peripheral tissues are resistant 3
Key Clinical Point: IR Occurs Independent of Weight
A critical pitfall is assuming lean PCOS patients don't have insulin resistance. The evidence clearly demonstrates:
- Nonobese women with PCOS have a 10-15% prevalence of impaired glucose tolerance 4
- Meta-analysis shows an inherent 27% reduction in insulin sensitivity in PCOS independent of BMI 5
- East Asian women exhibit significant insulin resistance despite lower BMI compared to Western populations 1
- However, obesity does exacerbate IR by an additional 15% in PCOS patients compared to controls 5
Mandatory Screening Approach
The Endocrine Society guideline mandates screening for glucose abnormalities in all PCOS patients 4:
Primary Screening Method
- Oral glucose tolerance test (OGTT) with fasting and 2-hour glucose using 75g glucose load 4
- This is superior to HbA1c, which has poor sensitivity for detecting impaired glucose tolerance 4
- HbA1c may be used only if patient is unable or unwilling to complete OGTT 4
Screening Frequency
- Repeat every 3-5 years, or more frequently if:
- Central adiposity develops
- Substantial weight gain occurs
- Symptoms of diabetes emerge 4
Additional Metabolic Screening
For patients with metabolic risk factors and/or confirmed IR, screen for:
- Non-alcoholic fatty liver disease (NAFLD) using serum liver enzymes 4
- NAFLD prevalence ranges 15-60% in PCOS depending on obesity and ethnicity 4
Clinical Markers of Insulin Resistance
Beyond formal testing, low sex hormone-binding globulin (SHBG) serves as a valuable clinical marker:
- Low SHBG is associated with reduced insulin sensitivity (10% reduction) 5
- This association is independent of BMI 5
Why This Matters for Management
Understanding that your patient likely has insulin resistance fundamentally changes the treatment hierarchy:
Lifestyle modification becomes first-line therapy for all PCOS patients 6
Insulin sensitizers (metformin) address the core pathophysiology by:
- Repairing mitochondrial dysfunction
- Decreasing oxidative stress
- Reducing androgen levels
- Enhancing insulin sensitivity 3
The 5- to 10-fold increased risk of type 2 diabetes in PCOS 4 makes early identification and intervention critical for preventing long-term morbidity
Phenotype Considerations
There is no clear difference in insulin sensitivity between NIH criteria versus Rotterdam criteria PCOS diagnoses 5, though metabolic heterogeneity exists between clinical phenotypes 7. The safest clinical approach is to assume IR is present and screen accordingly rather than risk missing this treatable component.
The evidence strongly supports that insulin resistance is a defining feature of PCOS pathophysiology, present in the majority of cases independent of obesity, and requires systematic screening and management to reduce both reproductive and cardiometabolic morbidity.